{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:59:58Z","timestamp":1791896398681,"version":"4.3.4"},"reference-count":186,"publisher":"Portland Press Ltd.","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The prevalence of diabetes and its related complications are increasing significantly globally. Collected evidence suggested that several genetic and environmental factors contribute to diabetes mellitus. Associated complications such as retinopathy, neuropathy, nephropathy and other cardiovascular complications are a direct result of diabetes. Epigenetic factors include deoxyribonucleic acid (DNA) methylation and histone post-translational modifications. These factors are directly related with pathological factors such as oxidative stress, generation of inflammatory mediators and hyperglycemia. These result in altered gene expression and targets cells in the pathology of diabetes mellitus without specific changes in a DNA sequence. Environmental factors and malnutrition are equally responsible for epigenetic states. Accumulated evidence suggested that environmental stimuli alter the gene expression that result in epigenetic changes in chromatin. Recent studies proposed that epigenetics may include the occurrence of \u2018metabolic memory\u2019 found in animal studies. Further study into epigenetic mechanism might give us new vision into the pathogenesis of diabetes mellitus and related complication thus leading to the discovery of new therapeutic targets. In this review, we discuss the possible epigenetic changes and mechanism that happen in diabetes mellitus type 1 and type 2 separately. We highlight the important epigenetic and non-epigenetic therapeutic targets involved in the management of diabetes and associated complications.<\/jats:p>","DOI":"10.1042\/bsr20202160","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T10:48:56Z","timestamp":1597920536000},"update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Epigenetic modification and therapeutic targets of diabetes mellitus"],"prefix":"10.1042","volume":"40","author":[{"given":"Rajveer","family":"Singh","sequence":"first","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research, Kolkata 164, Manicktala Main Road, Kolkata 700054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Chandel","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research, Kolkata 164, Manicktala Main Road, Kolkata 700054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhritiman","family":"Dey","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research, Kolkata 164, Manicktala Main Road, Kolkata 700054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arijit","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Department of Chemistry, University of Calcutta, Kolkata 700009, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syamal","family":"Roy","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research, Kolkata 164, Manicktala Main Road, Kolkata 700054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velayutham","family":"Ravichandiran","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research, Kolkata 164, Manicktala Main Road, Kolkata 700054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3266-9262","authenticated-orcid":false,"given":"Dipanjan","family":"Ghosh","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research, Kolkata 164, Manicktala Main Road, Kolkata 700054, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2020,9,10]]},"reference":[{"key":"2021111620261820200_B1","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1001\/jama.287.19.2570","article-title":"Diabetes and atherosclerosis: epidemiology, pathophysiology, and management","volume":"287","author":"Beckman","year":"2002","journal-title":"JAMA"},{"key":"2021111620261820200_B2","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1097\/01.ASN.0000065608.37756.58","article-title":"Overview: combating diabetic nephropathy","volume":"14","author":"Ziyadeh","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"2021111620261820200_B3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2337\/diacare.26.1.226","article-title":"Diabetic retinopathy","volume":"26","author":"Fong","year":"2003","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/01.ATV.0000133606.69732.4c","article-title":"Lipid inflammatory mediators in diabetic vascular disease","volume":"24","author":"Natarajan","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021111620261820200_B5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/B978-0-444-52902-2.00034-5","article-title":"Biology of diabetic neuropathy","volume":"115","author":"Vincent","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"2021111620261820200_B6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00045.2011","article-title":"Mechanisms of diabetic complications","volume":"93","author":"Forbes","year":"2013","journal-title":"Physiol. Rev."},{"key":"2021111620261820200_B7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"key":"2021111620261820200_B8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrneph.2014.116","article-title":"Diabetic nephropathy\u2014emerging epigenetic mechanisms","volume":"10","author":"Kato","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"2021111620261820200_B9","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.2337\/db10-1181","article-title":"Transcriptome analysis of human diabetic kidney disease","volume":"60","author":"Woroniecka","year":"2011","journal-title":"Diabetes"},{"key":"2021111620261820200_B10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature05913","article-title":"Perceptions of epigenetics","volume":"447","author":"Bird","year":"2007","journal-title":"Nature"},{"key":"2021111620261820200_B11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrneph.2014.116","article-title":"Diabetic nephropathy\u2014emerging epigenetic mechanisms","volume":"10","author":"Kato","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"2021111620261820200_B12","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00018-008-7324-y","article-title":"Methyl-CpG binding proteins: specialized transcriptional repressors or structural components of chromatin?","volume":"65","author":"Clouaire","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"2021111620261820200_B13","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/dmrr.1221","article-title":"Genome-wide association studies (GWAS): impact on elucidating the aetiology of diabetes","volume":"27","author":"Hakonarson","year":"2011","journal-title":"Diabetes Metab. Res. Rev."},{"key":"2021111620261820200_B14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/MED.0b013e32834872ce","article-title":"The epidemic of type 1 diabetes: what is it telling us?","volume":"18","author":"Forlenza","year":"2011","journal-title":"Curr. Opin. Endocrinol."},{"key":"2021111620261820200_B15","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.tibs.2005.12.008","article-title":"Genomic DNA methylation: the mark and its mediators","volume":"31","author":"Klose","year":"2006","journal-title":"Trends Biochem. Sci."},{"key":"2021111620261820200_B16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/ng1990","article-title":"Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome","volume":"39","author":"Weber","year":"2007","journal-title":"Nat. Genet."},{"key":"2021111620261820200_B17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/gene.2010.77","article-title":"DNA methylation dysregulates and silences the HLA-DQ locus by altering chromatin architecture","volume":"12","author":"Majumder","year":"2011","journal-title":"Genes Immun."},{"key":"2021111620261820200_B18","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3390\/genes8080209","article-title":"The genetic architecture of type 1 diabetes","volume":"8","author":"Jerram","year":"2017","journal-title":"Genes"},{"key":"2021111620261820200_B19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.trsl.2017.05.002","article-title":"Epigenetics and type 1 diabetes: mechanisms and translational applications","volume":"185","author":"Zullo","year":"2017","journal-title":"Transl. Res."},{"key":"2021111620261820200_B20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s12016-016-8592-1","article-title":"Beyond genetics: what causes type 1 diabetes","volume":"52","author":"Wang","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"2021111620261820200_B21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0036278","article-title":"Association of the CpG methylation pattern of the proximal insulin gene promoter with type 1 diabetes","volume":"7","author":"Fradin","year":"2012","journal-title":"PLoS ONE"},{"key":"2021111620261820200_B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152662","article-title":"Circulating differentially methylated amylin DNA as a biomarker of \u03b2-cell loss in type 1 diabetes","volume":"11","author":"Olsen","year":"2016","journal-title":"PLoS ONE"},{"key":"2021111620261820200_B23","doi-asserted-by":"publisher","first-page":"e68093","DOI":"10.1371\/journal.pone.0068093","article-title":"CpG methylation changes within the IL2RA promoter in type 1 diabetes of childhood onset","volume":"8","author":"Belot","year":"2013","journal-title":"PLoS ONE"},{"key":"2021111620261820200_B24","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nrg.2016.45","article-title":"Genetic sources of population epigenomic variation","volume":"17","author":"Taudt","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"2021111620261820200_B25","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"2021111620261820200_B26","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.bbagrm.2014.02.007","article-title":"Understanding the relationship between DNA methylation and histone lysine methylation","volume":"1839","author":"Rose","year":"2014","journal-title":"Biochim. Biophys. Acta Gene Regul. Mech."},{"key":"2021111620261820200_B27","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1042\/BST20170574","article-title":"Mammalian DNA methyltransferases: new discoveries and open questions","volume":"46","author":"Gowher","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"2021111620261820200_B28","doi-asserted-by":"publisher","first-page":"16335","DOI":"10.1074\/jbc.M111.330373","article-title":"Profiles of epigenetic histone post-translational modifications at type 1 diabetes susceptible genes","volume":"287","author":"Miao","year":"2012","journal-title":"J. Biol. Chem."},{"key":"2021111620261820200_B29","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.2337\/db08-0645","article-title":"Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes","volume":"57","author":"Miao","year":"2008","journal-title":"Diabetes"},{"key":"2021111620261820200_B30","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.cellimm.2009.10.012","article-title":"microRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients","volume":"260","author":"Hezova","year":"2010","journal-title":"Cell. Immunol."},{"key":"2021111620261820200_B31","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2337\/db09-0881","article-title":"Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory cytokines on pancreatic \u03b2-cells","volume":"59","author":"Roggli","year":"2010","journal-title":"Diabetes"},{"key":"2021111620261820200_B32","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.2337\/db11-1086","article-title":"Changes in microRNA expression contribute to pancreatic \u03b2-cell dysfunction in prediabetic NOD mice","volume":"61","author":"Roggli","year":"2012","journal-title":"Diabetes"},{"key":"2021111620261820200_B33","doi-asserted-by":"publisher","first-page":"896362","DOI":"10.1155\/2012\/896362","article-title":"Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression","volume":"2012","author":"Nielsen","year":"2012","journal-title":"Exp. Diabetes Res."},{"key":"2021111620261820200_B34","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/pedi.12015","article-title":"Genome wide association studies for diabetes: perspective on results and challenges","volume":"14","author":"Torres","year":"2013","journal-title":"Pediatr. Diabetes"},{"key":"2021111620261820200_B35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1399-5448.2009.00571.x","article-title":"The diagnosis and management of monogenic diabetes in children and adolescents","volume":"10","author":"Hattersley","year":"2009","journal-title":"Pediatr. Diabetes"},{"key":"2021111620261820200_B36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1210\/er.2009-0029","article-title":"Can the genetics of type 1 and type 2 diabetes shed light on the genetics of latent autoimmune diabetes in adults?","volume":"31","author":"Grant","year":"2010","journal-title":"Endocr. Rev."},{"key":"2021111620261820200_B37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1503\/cmaj.060244","article-title":"Type 1 diabetes: pathogenesis and prevention","volume":"175","author":"Gillespie","year":"2006","journal-title":"CMAJ"},{"key":"2021111620261820200_B38","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.2337\/db07-1331","article-title":"HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk: analysis of the type 1 diabetes genetics consortium families","volume":"57","author":"Erlich","year":"2008","journal-title":"Diabetes"},{"key":"2021111620261820200_B39","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/j.1399-0039.1995.tb02434.x","article-title":"Effects of the second HLA-DQ haplotype on the association with childhood insulin-dependent diabetes mellitus","volume":"45","author":"Sanjeevi","year":"1995","journal-title":"Tissue Antigens"},{"key":"2021111620261820200_B40","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2337\/diab.44.6.608","article-title":"HLA-DQB1* 0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM","volume":"44","author":"Pugliese","year":"1995","journal-title":"Diabetes"},{"key":"2021111620261820200_B41","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1542\/peds.111.4.860","article-title":"Clinical, autoimmune, and HLA characteristics of children diagnosed with type 1 diabetes before 5 years of age","volume":"111","author":"Hathout","year":"2003","journal-title":"Pediatrics"},{"key":"2021111620261820200_B42","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1038\/ng2068","article-title":"Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes","volume":"39","author":"Todd","year":"2007","journal-title":"Nat. Genet."},{"key":"2021111620261820200_B43","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nature05911","article-title":"Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls","volume":"447","author":"Wellcome Trust Case Control Consortium","year":"2007","journal-title":"Nature"},{"key":"2021111620261820200_B44","doi-asserted-by":"publisher","first-page":"290","DOI":"10.2337\/db08-1022","article-title":"Follow-up analysis of genome-wide association data identifies novel loci for type 1 diabetes","volume":"58","author":"Grant","year":"2009","journal-title":"Diabetes"},{"key":"2021111620261820200_B45","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/ng.381","article-title":"Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes","volume":"41","author":"Barrett","year":"2009","journal-title":"Nat. Genet."},{"key":"2021111620261820200_B46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11892-012-0321-4","article-title":"What will diabetes genomes tell us?","volume":"12","author":"Mohlke","year":"2012","journal-title":"Curr. Diabetes Rep."},{"key":"2021111620261820200_B47","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.coi.2012.09.001","article-title":"What have we learned from six years of GWAS in autoimmune diseases, and what is next?","volume":"24","author":"Hu","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"2021111620261820200_B48","doi-asserted-by":"publisher","first-page":"e1002293","DOI":"10.1371\/journal.pgen.1002293","article-title":"A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci","volume":"7","author":"Bradfield","year":"2011","journal-title":"PLoS Genet."},{"key":"2021111620261820200_B49","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1126\/science.1167728","article-title":"Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes","volume":"324","author":"Nejentsev","year":"2009","journal-title":"Science"},{"key":"2021111620261820200_B50","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/ng1802","article-title":"Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mellitus and congenital hypothyroidism","volume":"38","author":"Sen\u00e9e","year":"2006","journal-title":"Nat. Genet."},{"key":"2021111620261820200_B51","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gene.2008.99","article-title":"Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23\/TNFAIP3 as a susceptibility locus","volume":"10","author":"Fung","year":"2009","journal-title":"Genes Immun."},{"key":"2021111620261820200_B52","doi-asserted-by":"publisher","first-page":"e1000792","DOI":"10.1371\/journal.pgen.1000792","article-title":"Autoimmune disease classification by inverse association with SNP alleles","volume":"5","author":"Sirota","year":"2009","journal-title":"PLoS Genet."},{"key":"2021111620261820200_B53","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nrg3461","article-title":"Pleiotropy in complex traits: challenges and strategies","volume":"14","author":"Solovieff","year":"2013","journal-title":"Nat. Rev. Genet."},{"key":"2021111620261820200_B54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nrg2489","article-title":"Detecting shared pathogenesis from the shared genetics of immune-related diseases","volume":"10","author":"Zhernakova","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"2021111620261820200_B55","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/gm305","article-title":"Emerging patterns of genetic overlap across autoimmune disorders","volume":"4","author":"Richard-Miceli","year":"2012","journal-title":"Genome Med."},{"key":"2021111620261820200_B56","doi-asserted-by":"crossref","first-page":"R175","DOI":"10.1186\/ar3139","article-title":"Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease","volume":"12","author":"Eyre","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"2021111620261820200_B57","doi-asserted-by":"publisher","first-page":"e1002254","DOI":"10.1371\/journal.pgen.1002254","article-title":"Pervasive sharing of genetic effects in autoimmune disease","volume":"7","author":"Cotsapas","year":"2011","journal-title":"PLoS Genet."},{"key":"2021111620261820200_B58","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes: estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B59","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1210\/jc.2008-1345","article-title":"The genetics of type 2 diabetes: a realistic appraisal in 2008","volume":"93","author":"Florez","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021111620261820200_B60","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1042\/CS20080090","article-title":"Genetic determinants and molecular pathways in the pathogenesis of Type 2 diabetes","volume":"116","author":"Jin","year":"2009","journal-title":"Clin. Sci."},{"key":"2021111620261820200_B61","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/ajcn\/70.5.811","article-title":"Obesity at the age of 50 y in men and women exposed to famine prenatally","volume":"70","author":"Ravelli","year":"1999","journal-title":"Am. J. Clin. Nutr."},{"key":"2021111620261820200_B62","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1136\/bmj.303.6809.1019","article-title":"Fetal and infant growth and impaired glucose tolerance at age 64","volume":"303","author":"Hales","year":"1991","journal-title":"BMJ"},{"key":"2021111620261820200_B63","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/nature04048","article-title":"Reversing histone methylation","volume":"436","author":"Bannister","year":"2005","journal-title":"Nature"},{"key":"2021111620261820200_B64","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1101\/gad.1324305","article-title":"RNA meets chromatin","volume":"19","author":"Bernstein","year":"2005","journal-title":"Genes Dev."},{"key":"2021111620261820200_B65","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.molcel.2005.06.023","article-title":"The dynamics of chromatin remodeling at promoters","volume":"19","author":"Mellor","year":"2005","journal-title":"Mol. Cell"},{"key":"2021111620261820200_B66","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrg1688","article-title":"The role of chromatin structure in regulating the expression of clustered genes","volume":"6","author":"Sproul","year":"2005","journal-title":"Nat. Rev. Genet."},{"key":"2021111620261820200_B67","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1101\/gad.6.5.705","article-title":"Developmental pattern of gene-specific DNA methylation in the mouse embryo and germ line","volume":"6","author":"Kafri","year":"1992","journal-title":"Genes Dev."},{"key":"2021111620261820200_B68","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1242\/dev.99.3.371","article-title":"Temporal and regional changes in DNA methylation in the embryonic, extraembryonic and germ cell lineages during mouse embryo development","volume":"99","author":"Monk","year":"1987","journal-title":"Development"},{"key":"2021111620261820200_B69","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrg2540","article-title":"Linking DNA methylation and histone modification: patterns and paradigms","volume":"10","author":"Cedar","year":"2009","journal-title":"Nat. Rev. Genet."},{"key":"2021111620261820200_B70","doi-asserted-by":"publisher","first-page":"9103","DOI":"10.1128\/MCB.20.24.9103-9112.2000","article-title":"Genomic targeting of methylated DNA: influence of methylation on transcription, replication, chromatin structure, and histone acetylation","volume":"20","author":"Sch\u00fcbeler","year":"2000","journal-title":"Mol. Cell. Biol."},{"key":"2021111620261820200_B71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.mrfmmm.2008.08.006","article-title":"DNA methylation in development and human disease","volume":"647","author":"Gopalakrishnan","year":"2008","journal-title":"Mutat. Res."},{"key":"2021111620261820200_B72","first-page":"2316","article-title":"Development of type 2 diabetes following intrauterine growth retardation in rats is associated with progressive epigenetic silencing of Pdx1","volume":"118","author":"Park","year":"2008","journal-title":"J. Clin. Invest."},{"key":"2021111620261820200_B73","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1042\/bj3410315","article-title":"Upstream stimulatory factor regulates Pdx-1 gene expression in differentiated pancreatic \u03b2-cells","volume":"341","author":"Jin","year":"1999","journal-title":"Biochem. J."},{"key":"2021111620261820200_B74","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1074\/jbc.271.4.2294","article-title":"Pancreatic islet expression of the homeobox factor STF-1 relies on an E-box motif that binds USF","volume":"271","author":"Sharma","year":"1996","journal-title":"J. Biol. Chem."},{"key":"2021111620261820200_B75","doi-asserted-by":"publisher","first-page":"19489","DOI":"10.1074\/jbc.M513249200","article-title":"The histone methyltransferase SETDB1 and the DNA methyltransferase DNMT3A interact directly and localize to promoters silenced in cancer cells","volume":"281","author":"Li","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2021111620261820200_B76","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S1535-6108(02)00234-9","article-title":"Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene","volume":"3","author":"Bachman","year":"2003","journal-title":"Cancer Cell"},{"key":"2021111620261820200_B77","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0959-437X(02)00287-3","article-title":"Histone methylation in transcriptional control","volume":"12","author":"Kouzarides","year":"2002","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2021111620261820200_B78","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/msb.2012.61","article-title":"High-throughput sequencing for biology and medicine","volume":"9","author":"Soon","year":"2013","journal-title":"Mol. Syst. Biol."},{"key":"2021111620261820200_B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mce.2008.07.006","article-title":"Pancreatic transcription factors and their role in the birth, life and survival of the pancreatic \u03b2 cell","volume":"294","author":"Bernardo","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"2021111620261820200_B80","doi-asserted-by":"publisher","first-page":"E935","DOI":"10.1152\/ajpendo.00342.2004","article-title":"GLUT4 expression and subcellular localization in the intrauterine growth-restricted adult rat female offspring","volume":"288","author":"Thamotharan","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2021111620261820200_B81","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s00125-005-1669-7","article-title":"Low birthweight is associated with specific changes in muscle insulin-signalling protein expression","volume":"48","author":"Ozanne","year":"2005","journal-title":"Diabetologia"},{"key":"2021111620261820200_B82","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1113\/jphysiol.2004.076158","article-title":"Control of muscle glucose uptake: test of the rate-limiting step paradigm in conscious, unrestrained mice","volume":"562","author":"Fueger","year":"2005","journal-title":"J. Physiol."},{"key":"2021111620261820200_B83","doi-asserted-by":"publisher","first-page":"E38","DOI":"10.1152\/ajpendo.90306.2008","article-title":"Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology","volume":"295","author":"Karnieli","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2021111620261820200_B84","doi-asserted-by":"publisher","first-page":"40557","DOI":"10.1074\/jbc.M306609200","article-title":"Differential regulation of the muscle-specific GLUT4 enhancer in regenerating and adult skeletal muscle","volume":"278","author":"Moreno","year":"2003","journal-title":"J. Biol. Chem."},{"key":"2021111620261820200_B85","doi-asserted-by":"publisher","first-page":"13611","DOI":"10.1074\/jbc.M800128200","article-title":"Histone code modifications repress glucose transporter 4 expression in the intrauterine growth-restricted offspring","volume":"283","author":"Raychaudhuri","year":"2008","journal-title":"J. Biol. Chem."},{"key":"2021111620261820200_B86","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.2337\/db08-1666","article-title":"Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail","volume":"58","author":"Brasacchio","year":"2009","journal-title":"Diabetes"},{"key":"2021111620261820200_B87","doi-asserted-by":"publisher","first-page":"21087","DOI":"10.3390\/ijms141021087","article-title":"Cancer development, progression, and therapy: an epigenetic overview","volume":"14","author":"Sarkar","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"2021111620261820200_B88","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2217\/epi.14.4","article-title":"Do epigenetic drug treatments hold the key to killing cancer progenitor cells?","volume":"6","author":"Byler","year":"2014","journal-title":"Epigenomics"},{"key":"2021111620261820200_B89","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.drudis.2015.12.001","article-title":"Are epigenetic drugs for diabetes and obesity at our door step?","volume":"21","author":"Arguelles","year":"2016","journal-title":"Drug Discov. Today"},{"key":"2021111620261820200_B90","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.diabres.2016.11.009","article-title":"Epigenetic control of \u03b2-cell function and failure","volume":"123","author":"Bernstein","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"2021111620261820200_B91","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.phrs.2016.09.009","article-title":"Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes","volume":"113","author":"Sharma","year":"2016","journal-title":"Pharmacol. Res."},{"key":"2021111620261820200_B92","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/dmrr.559","article-title":"Role of histone and transcription factor acetylation in diabetes pathogenesis","volume":"21","author":"Gray","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"key":"2021111620261820200_B93","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1007\/s00125-010-1892-8","article-title":"Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines","volume":"53","author":"Lundh","year":"2010","journal-title":"Diabetologia"},{"key":"2021111620261820200_B94","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00125-016-4113-2","article-title":"HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells","volume":"60","author":"Daneshpajooh","year":"2017","journal-title":"Diabetologia"},{"key":"2021111620261820200_B95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20081029","article-title":"Glucose regulation of insulin gene expression in pancreatic \u03b2-cells","volume":"415","author":"Andrali","year":"2008","journal-title":"Biochem. J."},{"key":"2021111620261820200_B96","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2119\/molmed.2011.00021","article-title":"Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus","volume":"17","author":"Christensen","year":"2011","journal-title":"Mol. Med."},{"key":"2021111620261820200_B97","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1139\/bcb-2015-0057","article-title":"Does epigenetic dysregulation of pancreatic islets contribute to impaired insulin secretion and type 2 diabetes?","volume":"93","author":"Dayeh","year":"2015","journal-title":"Biochem. Cell. Biol."},{"key":"2021111620261820200_B98","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s00125-010-1967-6","article-title":"Insulin promoter DNA methylation correlates negatively with insulin gene expression and positively with HbA 1c levels in human pancreatic islets","volume":"54","author":"Yang","year":"2011","journal-title":"Diabetologia"},{"key":"2021111620261820200_B99","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1210\/me.2012-1004","article-title":"Increased DNA methylation and decreased expression of PDX-1 in pancreatic islets from patients with type 2 diabetes","volume":"26","author":"Yang","year":"2012","journal-title":"Mol. Endocrinol."},{"key":"2021111620261820200_B100","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1507\/endocrj.K07E-041","article-title":"PDX-1 and MafA play a crucial role in pancreatic \u03b2-cell differentiation and maintenance of mature \u03b2-cell function","volume":"55","author":"Kaneto","year":"2007","journal-title":"Endocr. J."},{"key":"2021111620261820200_B101","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s00125-007-0916-5","article-title":"Epigenetic regulation of PPARGC1A in human type 2 diabetic islets and effect on insulin secretion","volume":"51","author":"Ling","year":"2008","journal-title":"Diabetologia"},{"key":"2021111620261820200_B102","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1471-2350-14-76","article-title":"DNA methylation of the glucagon-like peptide 1 receptor (GLP1R) in human pancreatic islets","volume":"14","author":"Hall","year":"2013","journal-title":"BMC Med. Genet."},{"key":"2021111620261820200_B103","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.2337\/db09-0536","article-title":"SIRT1 genetic variation is related to BMI and risk of obesity","volume":"58","author":"Zillikens","year":"2009","journal-title":"Diabetes"},{"key":"2021111620261820200_B104","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nature01667","article-title":"Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1\u03b1 interaction","volume":"423","author":"Puigserver","year":"2003","journal-title":"Nature"},{"key":"2021111620261820200_B105","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1038\/sj.emboj.7600244","article-title":"Modulation of NF-\u03baB-dependent transcription and cell survival by the SIRT1 deacetylase","volume":"23","author":"Yeung","year":"2004","journal-title":"EMBO J."},{"key":"2021111620261820200_B106","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1128\/MCB.00705-08","article-title":"SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes","volume":"29","author":"Yoshizaki","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"2021111620261820200_B107","doi-asserted-by":"publisher","first-page":"E419","DOI":"10.1152\/ajpendo.00417.2009","article-title":"SIRT1 inhibits inflammatory pathways in macrophages and modulates insulin sensitivity","volume":"298","author":"Yoshizaki","year":"2009","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"2021111620261820200_B108","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1128\/MCB.00657-10","article-title":"Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress","volume":"30","author":"Schug","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"2021111620261820200_B109","doi-asserted-by":"publisher","first-page":"645","DOI":"10.15252\/embr.201643184","article-title":"Adipocyte SIRT1 controls systemic insulin sensitivity by modulating macrophages in adipose tissue","volume":"18","author":"Hui","year":"2017","journal-title":"EMBO Rep."},{"key":"2021111620261820200_B110","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.mce.2011.01.008","article-title":"Phosphoinositide 3-kinase as a novel functional target for the regulation of the insulin signaling pathway by SIRT1","volume":"335","author":"Fr\u00f6jd\u00f6","year":"2011","journal-title":"Mol. Cell. Endocrinol."},{"key":"2021111620261820200_B111","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/sj.emboj.7601633","article-title":"Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1\/PGC-1\u03b1","volume":"26","author":"Gerhart-Hines","year":"2007","journal-title":"EMBO J."},{"key":"2021111620261820200_B112","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1073\/pnas.061035098","article-title":"Restoration of insulin-sensitive glucose transporter (GLUT4) gene expression in muscle cells by the transcriptional coactivator PGC-1","volume":"98","author":"Michael","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021111620261820200_B113","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1172\/JCI29126","article-title":"Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome","volume":"116","author":"Kadowaki","year":"2006","journal-title":"J. Clin. Invest."},{"key":"2021111620261820200_B114","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.2337\/diacare.26.7.2015","article-title":"Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study","volume":"26","author":"Daimon","year":"2003","journal-title":"Diabetes Care."},{"key":"2021111620261820200_B115","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0140-6736(03)12255-6","article-title":"Adiponectin and protection against type 2 diabetes mellitus","volume":"361","author":"Spranger","year":"2003","journal-title":"Lancet North Am. Ed."},{"key":"2021111620261820200_B116","doi-asserted-by":"publisher","first-page":"39915","DOI":"10.1074\/jbc.M607215200","article-title":"SIRT1 regulates adiponectin gene expression through Foxo1-C\/enhancer-binding protein \u03b1 transcriptional complex","volume":"281","author":"Qiao","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2021111620261820200_B117","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1038\/nature08991","article-title":"Adiponectin and AdipoR1 regulate PGC-1\u03b1 and mitochondria by Ca 2+ and AMPK\/SIRT1","volume":"464","author":"Iwabu","year":"2010","journal-title":"Nature"},{"key":"2021111620261820200_B118","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/0166-6851(96)02592-3","article-title":"Protein phosphotyrosine phosphatases in Ascaris suum muscle","volume":"77","author":"Schmid","year":"1996","journal-title":"Mol. Biochem. Parasitol."},{"key":"2021111620261820200_B119","first-page":"737","article-title":"Protein-tyrosine phosphatase expression in pre-B cell NALM-6","volume":"52","author":"Adachi","year":"1992","journal-title":"Cancer Res."},{"key":"2021111620261820200_B120","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1182\/blood.V78.9.2222.2222","article-title":"Identification of novel protein tyrosine phosphatases of hematopoietic cells by polymerase chain reaction amplification","volume":"78","author":"Yi","year":"1991","journal-title":"Blood"},{"key":"2021111620261820200_B121","first-page":"58","article-title":"Protein-tyrosine phosphatase 1B substrates and metabolic regulation","volume-title":"Semin. Cell Dev. Biol.","author":"Bakke","year":"2015"},{"key":"2021111620261820200_B122","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1074\/jbc.M610096200","article-title":"The role of the C-terminal domain of protein tyrosine phosphatase-1B in phosphatase activity and substrate binding","volume":"282","author":"Picha","year":"2007","journal-title":"J. Biol. Chem."},{"key":"2021111620261820200_B123","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2337\/db13-1455","article-title":"Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade","volume":"63","author":"Aulinger","year":"2014","journal-title":"Diabetes"},{"key":"2021111620261820200_B124","doi-asserted-by":"publisher","first-page":"588","DOI":"10.2337\/diabetes.52.3.588","article-title":"Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo","volume":"52","author":"Ring","year":"2003","journal-title":"Diabetes"},{"key":"2021111620261820200_B125","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet North Am. Ed."},{"key":"2021111620261820200_B126","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1517\/13543784.13.9.1091","article-title":"Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes?","volume":"13","author":"Deacon","year":"2004","journal-title":"Exp. Opin. Investig. Drugs"},{"key":"2021111620261820200_B127","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.2337\/diab.46.8.1319","article-title":"Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-\u03b1 in humans: no alteration in adipose tissue of obese and NIDDM patients","volume":"46","author":"Auboeuf","year":"1997","journal-title":"Diabetes"},{"key":"2021111620261820200_B128","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nature09291","article-title":"Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR\u03b3 by Cdk5","volume":"466","author":"Choi","year":"2010","journal-title":"Nature"},{"key":"2021111620261820200_B129","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.2337\/diab.46.7.1230","article-title":"PPAR- \u03b3 gene expression is elevated in skeletal muscle of obese and type II diabetic subjects","volume":"46","author":"Park","year":"1997","journal-title":"Diabetes"},{"key":"2021111620261820200_B130","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s001250050048","article-title":"Distribution of peroxisome proliferator-activated receptors (PPARs) in human skeletal muscle and adipose tissue: relation to insulin action","volume":"43","author":"Loviscach","year":"2000","journal-title":"Diabetologia"},{"key":"2021111620261820200_B131","doi-asserted-by":"publisher","first-page":"699","DOI":"10.2337\/diabetes.48.4.699","article-title":"Insulin acutely regulates the expression of the peroxisome proliferator-activated receptor-gamma in human adipocytes","volume":"48","author":"Rieusset","year":"1999","journal-title":"Diabetes"},{"key":"2021111620261820200_B132","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.2307\/24105106","article-title":"Current concepts of PPAR-y signaling in diabetes","volume":"79","author":"Balasubramanyam","year":"2000","journal-title":"Curr. Sci."},{"key":"2021111620261820200_B133","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1146\/annurev.med.53.082901.104018","article-title":"The mechanisms of action of PPARs","volume":"53","author":"Berger","year":"2002","journal-title":"Annu. Rev. Med."},{"key":"2021111620261820200_B134","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.2337\/diab.43.10.1203","article-title":"A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat","volume":"43","author":"Oakes","year":"1994","journal-title":"Diabetes"},{"key":"2021111620261820200_B135","doi-asserted-by":"publisher","first-page":"25651","DOI":"10.1074\/jbc.C100189200","article-title":"Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor \u03b3 agonists","volume":"276","author":"Way","year":"2001","journal-title":"J. Biol. Chem."},{"key":"2021111620261820200_B136","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1210\/endo.142.3.8037","article-title":"Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor \u03b3 activation has coordinate effects on gene expression in multiple insulin-sensitive tissues","volume":"142","author":"Way","year":"2001","journal-title":"Endocrinology"},{"key":"2021111620261820200_B137","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1210\/endo.142.4.8114","article-title":"Minireview: 11\u03b2-hydroxysteroid dehydrogenase type 1\u2014a tissue-specific amplifier of glucocorticoid action","volume":"142","author":"Seckl","year":"2001","journal-title":"Endocrinology"},{"key":"2021111620261820200_B138","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.2337\/dc12-2391","article-title":"Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study","volume":"36","author":"Polidori","year":"2013","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B139","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","article-title":"LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial","volume":"92","author":"Zambrowicz","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"2021111620261820200_B140","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2016.10.017","article-title":"The Na+-D-glucose cotransporters SGLT1 and SGLT2 are targets for the treatment of diabetes and cancer","volume":"170","author":"Koepsell","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"2021111620261820200_B141","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1159\/000454951","article-title":"Two cases of mistaken polyuria and nephrocalcinosis in infants with glucose-galactose malabsorption: a possible role of 1, 25 (OH)2D3","volume":"87","author":"Fiscaletti","year":"2017","journal-title":"Horm. Res. Paediatr."},{"key":"2021111620261820200_B142","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/ki.2010.509","article-title":"Glucose handling by the kidney","volume":"79","author":"Mather","year":"2011","journal-title":"Kidney Int."},{"key":"2021111620261820200_B143","first-page":"93","article-title":"Insulin and renal sodium handling: clinical implications","volume":"5","author":"DeFronzo","year":"1981","journal-title":"Int. J. Obes."},{"key":"2021111620261820200_B144","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/jc.2011-2098","article-title":"Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline","volume":"97","author":"Umpierrez","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2021111620261820200_B145","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2337\/dc09-9029","article-title":"American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control","volume":"32","author":"Moghissi","year":"2009","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B146","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2337\/dc10-1407","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery)","volume":"34","author":"Umpierrez","year":"2011","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B147","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.2337\/dc07-0295","article-title":"Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial)","volume":"30","author":"Umpierrez","year":"2007","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B148","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2217\/epi.13.61","article-title":"Effect of exercise on DNA methylation and metabolism in human adipose tissue and skeletal muscle","volume":"5","author":"R\u00f6nn","year":"2013","journal-title":"Epigenomics"},{"key":"2021111620261820200_B149","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1161\/CIRCGENETICS.114.000671","article-title":"Adverse epigenetic signatures by histone methyltransferase Set7 contribute to vascular dysfunction in patients with type 2 diabetes mellitus","volume":"8","author":"Paneni","year":"2015","journal-title":"Circ. Cardiovasc. Genet."},{"key":"2021111620261820200_B150","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/1573399054022794","article-title":"Basal bolus dosing: a clinical experience","volume":"1","author":"King","year":"2005","journal-title":"Curr. Diabetes Rev."},{"key":"2021111620261820200_B151","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/jhm.101","article-title":"Glycemic chaos (not glycemic control) still the rule for inpatient care: how do we stop the insanity?","volume":"1","author":"Umpierrez","year":"2006","journal-title":"J. Hosp. Med."},{"key":"2021111620261820200_B152","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/jama.2008.943","article-title":"Sliding scale insulin\u2014time to stop sliding","volume":"301","author":"Hirsch","year":"2009","journal-title":"JAMA"},{"key":"2021111620261820200_B153","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1016\/S0140-6736(12)60780-6","article-title":"Choosing a blood-glucose-lowering agent after metformin","volume":"9833","author":"Diamant","year":"2012","journal-title":"Lancet North Am. Ed."},{"key":"2021111620261820200_B154","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","article-title":"Mechanism by which metformin reduces glucose production in type 2 diabetes","volume":"49","author":"Hundal","year":"2000","journal-title":"Diabetes"},{"key":"2021111620261820200_B155","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1016\/j.amjmed.2007.01.005","article-title":"Therapeutic options for modifying cardiometabolic risk factors","volume":"120","author":"Aronne","year":"2007","journal-title":"Am. J. Med."},{"key":"2021111620261820200_B156","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1758-5996-5-6","article-title":"Metformin: an old but still the best treatment for type 2 diabetes","volume":"5","author":"Rojas","year":"2013","journal-title":"Diabetol. Metab. Syndr."},{"key":"2021111620261820200_B157","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/MAJ.0b013e3182a562b7","article-title":"Metformin-associated lactic acidosis","volume":"349","author":"Pasquel","year":"2015","journal-title":"Am. J. Med. Sci."},{"key":"2021111620261820200_B158","doi-asserted-by":"publisher","first-page":"737","DOI":"10.2337\/diacare.15.6.737","article-title":"Sulfonylureas in NIDDM","volume":"15","author":"Groop","year":"1992","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B159","first-page":"789","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results","volume":"19","author":"Meinert","year":"1970","journal-title":"Diabetes"},{"key":"2021111620261820200_B160","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S0735-1097(98)00038-2","article-title":"The sulfonylurea controversy: more questions from the heart","volume":"31","author":"Brady","year":"1998","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021111620261820200_B161","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrendo.2011.243","article-title":"SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects","volume":"8","author":"Ferrannini","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"2021111620261820200_B162","doi-asserted-by":"publisher","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"2021111620261820200_B163","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","article-title":"Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus","volume":"85","author":"Komoroski","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"key":"2021111620261820200_B164","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.2337\/dc13-0277","article-title":"Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study","volume":"36","author":"Umpierrez","year":"2013","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B165","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1097\/CCM.0b013e31818b38d2","article-title":"Glycemic variability: a strong independent predictor of mortality in critically ill patients","volume":"36","author":"Krinsley","year":"2008","journal-title":"Crit. Care Med."},{"key":"2021111620261820200_B166","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4158\/EP13131.OR","article-title":"Glucose variability is an independent predictor of mortality in hospitalized patients treated with total parenteral nutrition","volume":"20","author":"Farrokhi","year":"2014","journal-title":"Endocr. Pract."},{"key":"2021111620261820200_B167","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2337\/diaspect.25.3.154","article-title":"Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"25","author":"Inzucchi","year":"2012","journal-title":"Diabetes Spectrum"},{"key":"2021111620261820200_B168","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.2337\/dc12-2060","article-title":"Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? The time has come for GLP-1 receptor agonists!","volume":"36","author":"Schwartz","year":"2013","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B169","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.2337\/dc12-2713","article-title":"A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe?","volume":"36","author":"Butler","year":"2013","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B170","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.2337\/dc12-2504","article-title":"A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks","volume":"36","author":"Nauck","year":"2013","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B171","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.clinthera.2012.04.012","article-title":"Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: a systematic review","volume":"34","author":"Derosa","year":"2012","journal-title":"Clin. Ther."},{"key":"2021111620261820200_B172","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2337\/dc08-9025","article-title":"Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"32","author":"Nathan","year":"2009","journal-title":"Diabetes Care"},{"key":"2021111620261820200_B173","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/ng.493","article-title":"The imprinted DLK1-MEG3 gene region on chromosome 14q32. 2 alters susceptibility to type 1 diabetes","volume":"42","author":"Wallace","year":"2010","journal-title":"Nat. Genet."},{"key":"2021111620261820200_B174","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1101\/gad.273821.115","article-title":"\u03b2linc1 encodes a long noncoding RNA that regulates islet \u03b2-cell formation and function","volume":"30","author":"Arnes","year":"2016","journal-title":"Genes Dev."},{"key":"2021111620261820200_B175","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1159\/000373999","article-title":"Downregulation of lncRNA TUG1 affects apoptosis and insulin secretion in mouse pancreatic \u03b2 cells","volume":"35","author":"Yin","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"key":"2021111620261820200_B176","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000488434","article-title":"Circulating LncRNAs analysis in patients with type 2 diabetes reveals novel genes influencing glucose metabolism and islet \u03b2-cell function","volume":"46","author":"Ruan","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"2021111620261820200_B177","doi-asserted-by":"crossref","first-page":"e1506","DOI":"10.1038\/cddis.2014.466","article-title":"Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus","volume":"5","author":"Liu","year":"2014","journal-title":"Cell Death Dis."},{"key":"2021111620261820200_B178","doi-asserted-by":"publisher","first-page":"e111715","DOI":"10.1371\/journal.pone.0111715","article-title":"A genome-wide association study for diabetic retinopathy in a Japanese population: potential association with a long intergenic non-coding RNA","volume":"9","author":"Awata","year":"2014","journal-title":"PLoS ONE"},{"key":"2021111620261820200_B179","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1161\/CIRCRESAHA.116.305510","article-title":"lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA","volume":"116","author":"Yan","year":"2015","journal-title":"Circ. Res."},{"key":"2021111620261820200_B180","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20170036","article-title":"Long non-coding RNA MIAT acts as a biomarker in diabetic retinopathy by absorbing miR-29b and regulating cell apoptosis","volume":"37","author":"Zhang","year":"2017","journal-title":"Biosci. Rep."},{"key":"2021111620261820200_B181","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrm.2015.32","article-title":"The biogenesis and emerging roles of circular RNAs","volume":"17","author":"Chen","year":"2016","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2021111620261820200_B182","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41576-019-0158-7","article-title":"The biogenesis, biology and characterization of circular RNAs","volume":"20","author":"Kristensen","year":"2019","journal-title":"Nat. Rev. Genet."},{"key":"2021111620261820200_B183","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature11928","article-title":"Circular RNAs are a large class of animal RNAs with regulatory potency","volume":"495","author":"Memczak","year":"2013","journal-title":"Nature"},{"key":"2021111620261820200_B184","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1161\/CIRCULATIONAHA.117.029004","article-title":"Circular noncoding RNA HIPK3 mediates retinal vascular dysfunction in diabetes mellitus","volume":"136","author":"Shan","year":"2017","journal-title":"Circulation"},{"key":"2021111620261820200_B185","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells9030659","article-title":"circRNAs signature as potential diagnostic and prognostic biomarker for diabetes mellitus and related cardiovascular complications","volume":"9","author":"Zaiou","year":"2020","journal-title":"Cells"},{"key":"2021111620261820200_B186","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1089\/ars.2017.7315","article-title":"Long noncoding RNAs in diabetes and diabetic complications","volume":"29","author":"Leung","year":"2018","journal-title":"Antioxid. Redox Signal."}],"container-title":["Bioscience Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20202160\/892817\/bsr-2020-2160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/bioscirep\/article-pdf\/doi\/10.1042\/BSR20202160\/892817\/bsr-2020-2160.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T20:55:18Z","timestamp":1637096118000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/bioscirep\/article\/40\/9\/BSR20202160\/226148\/Epigenetic-modification-and-therapeutic-targets-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":186,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9,30]]}},"URL":"https:\/\/doi.org\/10.1042\/bsr20202160","relation":{},"ISSN":["0144-8463","1573-4935"],"issn-type":[{"value":"0144-8463","type":"print"},{"value":"1573-4935","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,9]]},"article-number":"BSR20202160"}}